PCN427 ASSESSING THE PERFORMANCE OF PARAMETRIC SURVIVAL MODELS USING REAL WORLD EVIDENCE IN CML, LUNG AND PROSTATE CANCER von Paly, V.F., Zhang, S., Ndirangu, K., Shah, D., Mohanty, M.

Volltext

1105P Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial von Mohr, P., Larkin, J., Paly, V.F., Azocar, A. Remiro, Baio, G., Kurt, M., Amadi, A., Rizzo, J.I., Johnson, H.M., Moshyk, A., Kotapati, S., Middleton, M.

Volltext

PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMA... von Baker, T., Paly, V.F., Johnson, H.M., Van Campenhout, H., Amadi, A., Chandran, N., Moshyk, A., Kotapati, S.

Volltext

PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE... von Vallejo-Aparicio, L.A., Paly, V.F., Schroeder, M., Martin, A., Risebrough, N., Abreu, C., Biswas, C., Izquierdo Alonso, J.L., Riesco Miranda, J.A., Soler Cataluña, J.J., Ismaila, A.S.

Volltext